Alumis, an immunology drug developer on the cusp of Phase 3, will go public Friday in a smaller IPO than it originally projected.
The Bay …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Study uncovers that current safeguards against health disinformation in large language models (LLMs) are applied inconsistently, and AI developers lack transparency in their risk mitigation
Share this article Orphelia has developed Kizfizo as the first oral suspension of temozolomide to treat neuroblastoma. Credit: Nyaaka/Shutterstock.com Orphelia Pharma is taking action to
Young people who have used e-cigarettes are more than twice as likely to report experiencing chronic stress, according to research presented at the European Respiratory